Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis : extends deal to make Pfizer/BioNTech vaccines

10/21/2021 | 01:33am EST

ZURICH, Oct 21 (Reuters) - Novartis has agreed to expand its fill-and-finish support for the Pfizer/BioNTech COVID-19 vaccine by using manufacturing facilities Ljubljana, Slovenia, to fill at least 24 million doses in 2022, the Swiss drugmaker said on Thursday.

Novartis plans to take bulk mRNA active ingredient from BioNTech and fill this into vials under sterile conditions for shipment back to BioNTech for distribution.

This new agreement follows an earlier deal for the fill and finish of more than 50 million doses in 2021 at the Novartis Stein site in Switzerland. (Reporting by Michael Shields Editing by Riham Alkousaa)


ę Reuters 2021
All news about NOVARTIS AG
03:19aDrugmakers cut prices by 62% on average to get China state insurance listing
RE
12/02GLOBAL MARKETS LIVE : Hermès, Walt Disney, Apple, Novartis, Square...
12/02MarketScreener's World Press Review - December 2, 2021
12/02Novartis Sees 4% Compound Annual Growth in Sales Through 2026
MT
12/02EUROPEAN MIDDAY BRIEFING - Stocks Tumble Again in -2-
DJ
12/02NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
DJ
12/02Novartis Says Top Drugs Should Fuel Sales Growth Through 2026
DJ
12/02Novartis expects new drugs to boost sales by at least 4% until 2026
RE
12/02Novartis Expects Over 4% Sales Growth Through To 2026
MT
12/02Novartis, UCB Partner to Jointly Develop, Commercialize Parkinson's Disease Drugs
MT
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2021 52 106 M - -
Net income 2021 13 854 M - -
Net Debt 2021 22 649 M - -
P/E ratio 2021 12,6x
Yield 2021 4,10%
Capitalization 179 B 180 B -
EV / Sales 2021 3,88x
EV / Sales 2022 3,66x
Nbr of Employees 108 000
Free-Float 85,7%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 80,21 $
Average target price 97,34 $
Spread / Average Target 21,4%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-11.78%179 510
JOHNSON & JOHNSON-0.18%413 555
ROCHE HOLDING AG17.62%341 509
PFIZER, INC.44.09%297 706
NOVO NORDISK A/S64.51%243 534
ELI LILLY AND COMPANY47.55%224 726